MRD-Guided Melanoma Trial Enrolls First Patients With Signatera
First patients enrolled in NCT07504796: Signatera-positive melanoma patients randomized at week six to ipilimumab escalation or continued nivolumab-relatlimab.
Topic
Nivolumab
Topic
Topic
Topic
First patients enrolled in NCT07504796: Signatera-positive melanoma patients randomized at week six to ipilimumab escalation or continued nivolumab-relatlimab.